ClinicalTrials.gg
TerminatedNCT05770882Updated Mar 11, 2025

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

A Phase 1/2 interventional study of Chidamide and Regorafenib in Hepatocellular Carcinoma (HCC), sponsored by Great Novel Therapeutics Biotech & Medicals Corporation. Terminated at 5 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Great Novel Therapeutics Biotech & Medicals Corporation · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The overall profile does not support development for Hepatocellular Carcinoma

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing regorafenib in Carcinoma, Hepatocellular — 7 open to participants now, 9 under way, none of them phase 3. regorafenib · Carcinoma, Hepatocellular.

Enrollment
17th of 22
7 · median 33
Started
2023
with 3 others
Phase 1/2
3 of 22
1 open now
Registered
17th of 22
by date
Lead sponsor
1 of 22
Great Novel Therapeutics Biotech & Medicals Corporation

Among the 22 studies testing regorafenib in Carcinoma, Hepatocellular, this one is the 17th largest by enrollment, is one of 4 that started in 2023, is one of 3 in phase 1/2, and was the 17th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 22 studies testing regorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing regorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This open-label, phase Ib/II, multicenter study evaluated the safety, tolerability, efficacy, and PK of chidamide in combination with regorafenib in patients with HCC. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor. Regorafenib, a receptor tyrosine kinase inhibitor, was approved as second-line systemic treatment for HCC patients.

Read the detailed description

This is an open-label, multicenter, phase Ib/II study, which includes a Part I (phase Ib) and a Cohort Expansion part (Part II; phase II). Part I of the study is designed to assess the safety, tolerability, PK profiles, efficacy, and PD biomarkers of the study medications in patients with HCC. Part II of the study is designed to assess the efficacy, safety, and PD biomarkers.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • HCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological or cytological confirmation of HCC or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria in patients with a confirmed diagnosis of cirrhosis.
  2. Barcelona Clinic Liver Cancer (BCLC) stage B or C HCC that cannot benefit from treatments of established efficacy with higher priority such as resection, local ablation, chemoembolization or systemic therapy.
  3. Has received and failed one front-line systemic treatment with either sorafenib, lenvatinib, or combination of /PD-L1 immune checkpoint inhibitor (ICI; anti-PD-1/PD-L1 mAb) plus bevacizumab, lenvatinib or anti-CTLA-4 mAb.
  4. Tolerability of prior treatment with sorafenib or lenvatinib. Tolerability to previous sorafenib treatment is defined as not less than 20 days at a minimum daily dose of 400 mg QD within the last 28 days prior to withdrawal. Tolerability to previous lenvatinib treatment is defined as not less than 20 days at a daily dose of 8 mg QD for patients ≥60 kg or 4 mg QD for patients \<60 kg days within the last 28 days prior to withdrawal.
  5. Liver function status Class A. Child-Pugh status should be calculated based on clinical findings and laboratory results during the screening period.
  6. Local or loco-regional therapy of intrahepatic tumor lesions (e.g., surgery, radiation therapy, hepatic arterial embolization or infusion chemotherapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks before the first dose of study medication.
  7. PS of 0 or 1.
  8. With adequate bone marrow, liver, and renal functions, as assessed by the following laboratory tests conducted within 7 days before the first dose of study medication:
  9. At least one uni-dimensional by computed tomography scan or magnetic resonance imaging according to (RECIST) v1.1 and modified RECIST for HCC (). Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.
  10. With a of at least 3 months.
  11. Females of and males must agree to use adequate since signing of the form until at least 2 months after the last study drug administration.
  12. Female patients of childbearing potential must have a negative urine or serum pregnancy test.
  13. Able to take oral medication.
  14. Has ability to understand and the willingness to provide a written informed consent document.

Exclusion criteria

Exclusion Criteria:

  1. With history of organ transplantation or candidates for liver transplantation.
  2. Prior treatment with regorafenib.
  3. treatment within 4 weeks before the first dose of study medication.
  4. Permanent discontinuation of prior sorafenib or lenvatinib therapy due to drug-related toxicity.
  5. Known history or symptomatic brain or meningeal tumors. Note: If patients showed symptomatic at screening, magnetic resonance imaging (MRI) or computed tomography (CT) scanning should be performed to demonstrate any current evidence of progressive brain metastases.
  6. Major surgical procedure or significant traumatic injury within 28 days before the first dose of study medication.
  7. With uncontrolled or significant cardiovascular diseases
  8. With the size of fluid area detected by cardiac ultrasonography in cavum pericardium ≥ 10 mm.
  9. Patients with pheochromocytoma.
  10. Uncontrolled ascites (defined as not easily controlled with diuretic or paracentesis treatment).
  11. Pleural effusion or ascites that causes respiratory compromise (National Cancer Institute - [NCI-CTCAE] v5.0 grade ≥2 dyspnea).
  12. Ongoing infection grade >2 according to NCI-CTCAE v5.0. is allowed if no active replication is present. is allowed if no antiviral treatment is required.
  13. bleeding NCI-CTCAE v5.0 grade ≥3 within 30 days before the first dose of study medication.
  14. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis, or pulmonary embolism within 6 months before the first dose of study medication..
  15. With disorders or history of organ transplantation who require therapy
  16. Non-healing wound, ulcer, or bone fracture.
  17. Renal failure requiring hemo- or peritoneal dialysis.
  18. Interstitial lung disease with ongoing signs and symptoms at the time of screening.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Part I safety; and Part II cohort expansion

    Part I: The safety of drug combination will be studied. Part II: The drug combination will be further evaluated in the cohort expansion phase.

    Drug: Chidamide · Drug: Regorafenib

Interventions

  • Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.

    Also known as: Tucidinostat, HBI-8000

  • Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.

    Also known as: Stivarga, BAY 73-4506

06

What researchers measure

Primary outcomes

  1. Adverse event (AE)

    To analyze the frequency, percentage of patients with study medications of adverse events

    Time frame: From the first day of treatment until progressive disease or death, assessed up to 12 months

  2. Maximum tolerated dose(MTD) / maximum feasible dose (MFD)

    To assess tolerability/feasible of study medications dose

    Time frame: From start of treatment Cycle1 Day1 until completion of one cycle of treatment (maximum 28 days)

  3. Pharmacokinetics profiles - (AUC0-t)

    Area under the plasma concentration-time curve from time zero to time t(AUC0-t)

    Time frame: Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle)

  4. Pharmacokinetics profiles - (AUC0-∞)

    Area under the plasma concentration-time curve from time zero to infinity(AUC0-∞)

    Time frame: Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle)

  5. Pharmacokinetics profiles - (Cmax)

    Maximum plasma concentration(Cmax)

    Time frame: Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle)

  6. Pharmacokinetics profiles - (Tmax)

    Time to maximum plasma concentration(Tmax)

    Time frame: Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle)

  7. Pharmacokinetics profiles - (T1/2)

    Half-life(T1/2)

    Time frame: Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle)

  8. Objective response rate (ORR)

    The percentage of patients with CR and PR of total number of analysis set

    Time frame: Objective Response Rate is assessed every 8 weeks from start of treatment until progressive disease is documented (approximately 6 months)

  9. Progression-free survival (PFS)

    The time from first day of dosing until the date of first objective disease progression or death

    Time frame: From the first day of treatment until disease progression or death from any cause, assessed up to 12 months

Secondary outcomes

  1. Overall survival (OS)

    The time from the first day of dosing until the date of death

    Time frame: 1 year

  2. Time to progression (TTP)

    The time from the first day of dosing until the date of progression

    Time frame: 1 year

07

Study locations

5 sites
  • Chang Gung Memorial Hospital, Kaohsiung
    Kaohsiung, Taiwan
  • China Medical University Hospital
    Taichung, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jan 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Mar 16, 2023
StartActual
Apr 25, 2023
Primary completionActual
Jan 17, 2025
CompletionActual
Jan 17, 2025
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05770882
Lead sponsor
Great Novel Therapeutics Biotech & Medicals Corporation
Responsible party
Sponsor
First posted
Mar 16, 2023
Start date
Apr 25, 2023
Primary completion
Jan 17, 2025
Completion
Jan 17, 2025
Last update
Mar 11, 2025

Study contacts

Chia-Nan Chen, Ph.D.
study director · Great Novel Therapeutics Biotech & Medicals Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Regorafenib

Start the discussion